person · Reporting owner
Stein Robert Benjamin
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MIMEDX GROUP, INC.MDXG · Entity 5271 | President, Regenerative Med. | May 15, 2023 | May 17, 2023 |
| PolyPid Ltd.PYPD · Entity 6713 | Director | July 15, 2026 | July 17, 2026 |
| Protagenic Therapeutics, Inc.\newPTIX · Entity 8496 | Director | March 25, 2024 | March 30, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MIMEDX GROUP, INC.
Report date May 15, 2023 · Filed May 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 317,803 |
Ending reported balance
After 2023-05-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-05-15 · Sale · Disposed 3,607 · Balance 328,168 F1: The purchase price indicated is a weighted average purchase price. The corresponding shares were bought in multiple transactions at prices ranging from $6.120 to $6.190, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth herein. Row 2 · 2023-05-16 · Sale · Disposed 10,365 · Balance 317,803 F2: The purchase price indicated is a weighted average purchase price. The corresponding shares were bought in multiple transactions at prices ranging from $5.870 to $6.025, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth herein. |
Filing footnotes · ownership attribution and instrument terms
F1: The purchase price indicated is a weighted average purchase price. The corresponding shares were bought in multiple transactions at prices ranging from $6.120 to $6.190, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth herein.
F2: The purchase price indicated is a weighted average purchase price. The corresponding shares were bought in multiple transactions at prices ranging from $5.870 to $6.025, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth herein.
PolyPid Ltd.
Report date July 15, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2036-07-15 | Direct | 9,132 |
Reported balance
After 2026-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 9,132 · Balance 9,132 F1: The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030.
Protagenic Therapeutics, Inc.\new
Report date March 25, 2024 · Filed March 30, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| PTIX Common stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2034-03-25 | Direct | 75,000 |
Reported balance
After 2024-03-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-25 · Grant · Acquired 75,000 · Balance 75,000 F1: 50,000 of the options are fully-exerciseable on March 25, 2026. The other 25,000 of the options are exercisable on and after the date upon which the company consummates a corporate partnership, if that occurs before December 31, 2026. If the company does not enter into a corporate partnership before December 31, 2026, then those 25,000 options are never exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: 50,000 of the options are fully-exerciseable on March 25, 2026. The other 25,000 of the options are exercisable on and after the date upon which the company consummates a corporate partnership, if that occurs before December 31, 2026. If the company does not enter into a corporate partnership before December 31, 2026, then those 25,000 options are never exercisable.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AGENUS INC
Report date March 31, 2017 · Filed April 04, 2017
Section 16 reporting ended · disclosed 2017-04-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option, Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $3.77 · Expires 2027-03-31 | Direct | 100,000 |
Reported balance
After 2017-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-31 · Grant · Acquired 100,000 · Balance 100,000 F1: Options vest one-third on the one-year anniversary of the grant date with the remainder vesting in equal quarterly installments provided the executive maintains a service relationship with the Company through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Options vest one-third on the one-year anniversary of the grant date with the remainder vesting in equal quarterly installments provided the executive maintains a service relationship with the Company through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 17, 2026 20:03 UTC | PolyPid Ltd. PYPD · Entity 6713 | GrantStock option (right to buy) · Derivative | 9,132 | $4.46 Strike: $4.46 | $40,728.72 |
DisclosureSEC source: 0001213900-26-079158 · ownership.xml · derivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,132 Underlying: Ordinary Shares · 9,132 shares Expires 2036-07-15 F1 · derivative.exercise_date: The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030. Read SEC document |
| March 25, 2024 Filed Mar 30, 2024 01:29 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | GrantPTIX Common stock Options · Derivative | 75,000 | $1.74 Strike: $1.74 | $130,500.00 |
DisclosureSEC source: 0001493152-24-012073 · ownership.xml · derivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: PTIX Common Stock, Par Value $0.0001 · 75,000 shares Expires 2034-03-25 F1 · derivative.exercise_date: 50,000 of the options are fully-exerciseable on March 25, 2026. The other 25,000 of the options are exercisable on and after the date upon which the company consummates a corporate partnership, if that occurs before December 31, 2026. If the company does not enter into a corporate partnership before December 31, 2026, then those 25,000 options are never exercisable. Read SEC document |
| May 16, 2023 Filed May 17, 2023 22:26 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | SaleCommon Stock | 10,365 | $5.95 | $61,627.18 |
DisclosureSEC source: 0001376339-23-000031 · wf-form4_168436236626701.xml · nonDerivative · entry 2 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 317,803 F2 · price: The purchase price indicated is a weighted average purchase price. The corresponding shares were bought in multiple transactions at prices ranging from $5.870 to $6.025, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth herein. Read SEC document |
| May 15, 2023 Filed May 17, 2023 22:26 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | SaleCommon Stock | 3,607 | $6.15 | $22,170.43 |
DisclosureSEC source: 0001376339-23-000031 · wf-form4_168436236626701.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 328,168 F1 · price: The purchase price indicated is a weighted average purchase price. The corresponding shares were bought in multiple transactions at prices ranging from $6.120 to $6.190, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth herein. Read SEC document |
| May 10, 2023 Filed May 12, 2023 22:56 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | SaleCommon Stock | 5,869 | $5.93 | $34,780.28 |
DisclosureSEC source: 0001376339-23-000028 · wf-form4_168393215769457.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 331,775 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. Read SEC document |
| May 04, 2023 Filed May 9, 2023 12:32 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | SaleCommon Stock | 51,756 | $5.34 | $276,470.20 |
DisclosureSEC source: 0001376339-23-000022 · wf-form4_168363556235229.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,644 F1 · price: The sale price indicated is a weighted average sale price. The corresponding shares were sold in multiple transactions at prices ranging from $5.125 to $5.540, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 23:24 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | SaleCommon Stock | 5,987 | $3.74 | $22,415.33 |
DisclosureSEC source: 0001628280-23-013697 · wf-form4_168263786872653.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 389,400 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 21:50 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | SaleCommon Stock | 5,996 | $3.31 | $19,846.76 |
DisclosureSEC source: 0001628280-23-011533 · wf-form4_168142263442757.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 395,387 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 22:26 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 135,065 | $4.62 | $624,000.30 |
DisclosureSEC source: 0001376339-23-000007 · wf-form4_167891919545041.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,383 F1 · shares: Reflects grant of restricted stock units which will be settled in common stock following vesting. Award vests pro rata annually over three years. Grant is exempt under Rule 16b-3. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 22:43 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | SaleCommon Stock | 12,355 | $4.24 | $52,442.03 |
DisclosureSEC source: 0001376339-23-000005 · wf-form4_167840178194084.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,318 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. Read SEC document |
| September 13, 2022 Filed Sep 15, 2022 00:17 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | SaleCommon Stock | 8,329 | $3.46 | $28,785.02 |
DisclosureSEC source: 0001376339-22-000114 · wf-form4_166320103466747.xml · nonDerivative · entry 2 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,673 Read SEC document |
| September 12, 2022 Filed Sep 15, 2022 00:17 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | SaleCommon Stock | 19,000 | $3.44 | $65,284.00 |
DisclosureSEC source: 0001376339-22-000114 · wf-form4_166320103466747.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,002 F1 · price: The sale price indicated is a weighted average sale price. The corresponding shares were sold in multiple transactions at prices ranging from $3.42 to $3.45, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 22:49 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | SaleCommon Stock | 8,503 | $4.04 | $34,343.62 |
DisclosureSEC source: 0001376339-22-000110 · wf-form4_166069016592798.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,002 F1 · kind: Reflects sale of shares to cover tax withholding obligation upon vesting of previously-granted award. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 21:43 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | SaleCommon Stock | 19,500 | $3.62 | $70,590.00 |
DisclosureSEC source: 0001376339-22-000103 · wf-form4_165999497107897.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,505 Read SEC document |
| June 28, 2022 Filed Jun 30, 2022 23:09 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | SaleCommon Stock | 14,600 | $3.47 | $50,662.00 |
DisclosureSEC source: 0001376339-22-000095 · wf-form4_165663054650638.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,005 F1 · price: The sale price indicated is a weighted average sale price. The corresponding shares were sold in multiple transactions at prices ranging from $3.47 to $3.48, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 21:24 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 178,571 | $4.62 | $824,998.02 |
DisclosureSEC source: 0001376339-22-000038 · wf-form4_164979866808881.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President, Regenerative Med. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,605 F1 · shares: Reflects grant of restricted stock units which will be settled in common stock following vesting. Award vests pro rata annually over three years. Grant is exempt under Rule 16b-3. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 21:21 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | SaleCommon Stock | 11,672 | $4.86 | $56,714.25 |
DisclosureSEC source: 0001376339-22-000021 · wf-form4_164694725686210.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,034 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. F2 · price: The sale price indicated is a weighted average sale price. The corresponding shares were sold in multiple transactions at prices ranging from $4.75 to $4.965, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:56 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | SaleCommon Stock | 9,362 | $11.85 | $110,967.79 |
DisclosureSEC source: 0001376339-21-000097 · wf-form4_162923376480953.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,706 F1 · kind: Represents shares sold to pay associated taxes upon vesting. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:17 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 109,235 | $0.00 | $0.00 |
DisclosureSEC source: 0001376339-21-000006 · wf-form4_161523822300592.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,068 F1 · shares: Reflects grant of restricted stock units which will be settled in common stock following vesting. Award vests pro rata annually over three years. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:36 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 81,833 | $6.11 | $499,999.63 |
DisclosureSEC source: 0001376339-20-000095 · wf-form4_159726459429104.xml · nonDerivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,833 F1 · kind: Represents grant of restricted stock which vests one-third each anniversary. Read SEC document |
| February 21, 2020 Filed Feb 27, 2020 01:32 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | GrantPTIX Common stock Options · Derivative | 150,000 | Not disclosed Strike: $1.75 | Not disclosed |
DisclosureSEC source: 0001493152-20-003043 · ownership.xml · derivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: PTIX Common Stock, Par Value $0.0001 · 150,000 shares Expires 2030-02-21 F1 · price: As this was an option grant, there was no cost to the recipient. Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 18:23 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | GrantNon-Qualified Stock Options (Right to Buy() · Derivative | 200,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001437749-17-017235 · rdgdoc.xml · derivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Protagenic Therapeutics, Inc. Common Stock · 200,000 shares Expires 2027-10-16 F1 · derivative.exercise_date: Vesting in equal installments over 18 months Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 22:42 UTC | AGENUS INC agen · Entity 5774 | GrantStock Option, Right to Buy · Derivative | 100,000 | $3.77 Strike: $3.77 | $377,000.00 |
DisclosureSEC source: 0001288123-17-000013 · primary_doc.xml · derivative · entry 1 Stein Robert Benjamin · CIK 0001597158 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-03-31 F1 · derivative.exercise_date: Options vest one-third on the one-year anniversary of the grant date with the remainder vesting in equal quarterly installments provided the executive maintains a service relationship with the Company through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.